ArticleAging2021
The risk of Alzheimer's disease according to dynamic changes in metabolic health and obesity: a nationwide population-based cohort study.
Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Dementia risk by metabolic health and obesity in two prospective cohorts.BMC medicine · 2026Article
- Association of metabolic obesity phenotypes with cognitive decline in the ELSA-Brasil study.Diabetes, obesity & metabolism · 2026Article
- Association of mild cognitive impairment and obesity-metabolic status in middle-aged and elderly adults: a nationwide prospective cohort study.Journal of neurology · 2026Review
- Body mass index, metabolically abnormal status, and incident Parkinson's disease: Data from the UK Biobank.Journal of Parkinson's disease · 2025Article
- How is the brain affected by metabolically healthy or unhealthy obesity in adulthood and elderly? A narrative review of neuroimaging and neurocognitive findings.Frontiers in aging neuroscience · 2025Review
- Associations of metabolic heterogeneity of obesity with the risk of dementia in middle-aged adults: three prospective studies.Alzheimer's research & therapy · 2024Article
- Is metabolic-healthy obesity associated with risk of dementia? An age-stratified analysis of the Whitehall II cohort study.BMC medicine · 2023Article
- Article
- Pathogenesis, Murine Models, and Clinical Implications of Metabolically Healthy Obesity.International journal of molecular sciences · 2022Review
- The Systemic Effects of Exercise on the Systemic Effects of Alzheimer's Disease.Antioxidants (Basel, Switzerland) · 2022Review
- Identification of diagnostic genes for both Alzheimer's disease and Metabolic syndrome by the machine learning algorithm.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the association of metabolic health and obesity phenotypes with the risk of Alzheimer's disease (AD). This study enrolled 136,847 elderly participants aged 60 or above from the Korean National Health Insurance System. At baseline examinations in 2009 and 2010, subjects were categorized into four groups: the metabolically healthy non-obese (MHNO), metabolically healthy obese (MHO), metabolically unhealthy non-obese (MUNO), and metabolically unhealthy obese (MUO) groups. Based on the phenotypic transition after 2 years, the subjects were further categorized into 16 subgroups. They were followed from 2009 to 2015 to monitor for AD development. The MHO phenotype protected subjects from AD, relative to the MHNO phenotype (HR, 0.73; 95% CI, 0.65-0.81). Among subjects initially classified as MHO, 41.8% remained MHO, with a significantly lower risk of AD compared with the stable MHNO group (HR, 0.62; 95% CI, 0.50-0.77). Among MUO subjects at baseline, those who changed phenotype to MUNO were at higher risk of AD (HR, 1.47; 95% CI, 1.28-1.70), and the transition to the MHO phenotype protected subjects from AD (HR, 0.62; 95% CI, 0.50-0.78). The MHO phenotype conferred a decreased risk of AD. Maintenance or recovery of metabolic health might mitigate AD risk among obese individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.